Peptide 101: Glutathione

Walk into any IV bar and glutathione is on the menu, usually near the top, usually the most expensive line. It gets sold for energy, for skin, for detox, for aging.

Here is the awkward part. Almost nothing about that menu is in dispute at the level of biology. Glutathione really is your body's master antioxidant. The dispute is about whether putting more of it in a bag and running it into your arm does anything for you. Those are two different questions, and the marketing depends on you not separating them.

Glutathione is a tripeptide — three amino acids strung together: glutamate, cysteine, and glycine. That makes it one of the few things in our library that is unambiguously a peptide.

Every cell in your body makes its own. It is the most abundant antioxidant you have, and it is central to three jobs: mopping up oxidative damage, helping the liver package toxins for disposal, and supporting immune cells.

Levels fall with age. They also drop with chronic illness, toxin exposure, and poor nutrition. That decline is real and well documented, and it is the hook every glutathione product hangs on.

You can buy it as an oral supplement, as a liposomal formulation (wrapped in fat bubbles to survive digestion), or as an IV or intramuscular injection.

Glutathione is the janitorial and recycling crew inside every cell. It sweeps up toxic waste, bags it for disposal, and recharges the other cleaning supplies so they can keep working.

The technical version: glutathione neutralizes reactive oxygen species and free radicals directly through its thiol group (a sulfur-hydrogen pair that is chemically eager to donate an electron), cycling between reduced GSH and oxidized GSSG forms via the glutathione peroxidase and glutathione reductase enzymes. It is essential to Phase II liver detoxification, where it conjugates with toxins and drug metabolites — chemically bolts itself onto them — to make them water-soluble enough to excrete. It also regenerates vitamins C and E, maintains protein thiol status, and supports T-cell and NK-cell function.

That recycling role is the underrated part. Glutathione is not just an antioxidant; it is what keeps your other antioxidants working.

Our read on the overall strength of the evidence: Strong Evidence.

The grade covers the biochemistry, which is about as settled as biology gets. What is thinner is the step everyone actually cares about: does supplementing raise your glutathione, and does raising it make you better off.

What that rests on:

Two things worth noticing. The human evidence above is for oral and liposomal forms at fairly modest endpoints — not for the IV drips that dominate the market. And the fact that liposomal formulations exist at all tells you something: getting swallowed glutathione into your bloodstream intact is the contested part of the whole field.

Note, preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

Generally very well tolerated, which is a fair part of why it is sold so freely.

Oral glutathione may cause mild GI symptoms, including bloating and cramping. IV glutathione can rarely cause allergic reactions, headache, or rash. Long-term high-dose IV use has been anecdotally associated with zinc depletion — anecdotally is the operative word, but worth raising if you are a regular. Inhaled glutathione can trigger bronchospasm (sudden airway tightening) in people with asthma.

Reasons to avoid it, or to talk to a clinician first:

This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.

Two mazdutide trials this week, both pushing it somewhere new.

ClinicalTrials.gov · mazdutide · interventional

A randomized, double-blind, placebo-controlled trial pairing mazdutide with a levonorgestrel-releasing IUD, in overweight and obese patients with atypical endometrial hyperplasia or early-stage endometrioid endometrial cancer. The goal is fertility-sparing management.

This is the more interesting of the two by some distance. Obesity is a well-established driver of endometrial cancer risk, and the question of whether treating the obesity changes the cancer outcome has largely been theoretical. Placebo-controlled, so it should give a real answer.

Source ↗

ClinicalTrials.gov · mazdutide · interventional

A first-in-human safety and pharmacokinetics study of IBI3046 in Chinese participants with overweight or obesity. Notably, it includes arms testing IBI3046 both after stopping mazdutide and in combination with it.

Phase 1 means safety and dosing, not effectiveness. The sequencing arm is what caught our eye — what to do after a patient comes off one of these drugs is a question the field keeps deferring.

Source ↗

About glutathione

Glutathione is not in our regulatory database. It has not been evaluated or approved by the U.S. Food and Drug Administration for any medical use. Discuss with your healthcare provider before considering any substance not reviewed here.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.